Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Imaging Chronic Active Lesions in Multiple Sclerosis: a Consensus Statement from the North America Imaging in Multiple Sclerosis Cooperative

Author:Bagnato, Francesca   Sati, Pascal   Hemond, Christopher   Elliott, Colm   Gauthier, Susan   Harrison, Daniel   Mainero, Caterina   Oh, Jiwon   Pitt, David   Shinohara, Russell   Smith, Seth   Bruce, Trapp   Azevedo, Christina   Calabresi, Peter   Henry, Roland   Laule, Cornelia   Ontaneda, Daniel   Rooney, William   Sicotte, Nancy   Reich, Daniel   Absinta, Martina   

Session Name:P11: MS Neuroimaging 2  

Topic:MS and Inflammatory Disease  

Program Number:P11.009  

Author Institution:Vanderbilt University Medical Center, Nashville, TN  Cedars-Sinai Medical Center, Los Angeles, CA  University of Massachusetts Memorial Medical Center, Worcester, MA  NeuroRx Research, Montreal, QC, Canada  Weill Cornell Medicine, New York, NY  University of Maryland School of Medicine, Baltimore, MD  Massachusettes General Hosptial, Charlestown, MA  St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada  Yale School of Medicine, New Haven, CT  University of Pennsylvania, Philadelphia, PA  Vanderbilt University Institute of Imaging Science, Nashville, TN  Cleveland Clinic, Cleveland, OH  University of Southern California, Los Angeles, CA  Johns Hopkins University, Baltimore, MD  University of California, San Francisco, San Francisco, CA  University of British Columbia, Vancouver, BC, Canada  Oregon Health & Science University, Portland, OR  National Institutes of Health, Neuroimmunology Branch, NINDS, Bethesda, MD  St. Raffaele Hospital, Milan, Italy  

Effect of Longer-term Ofatumumab Treatment on Disability Progression and Brain Volume Change

Author:Cohen, Jeffrey   Hauser, Stephen   Zielman, Ronald   Das Gupta, Ayan   Azmon, Amin   Xi, Jing   Mavrikis Cox, Gina   Robertson, Derrick   Wiendl, Heinz   Kappos, Ludwig   

Session Name:S16: MS Clinical Trials and Therapeutics  

Topic:MS and Inflammatory Disease  

Program Number:S16.009  

Author Institution:Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  UCSF Weill Institute for Neurosciences, Department of Neurology, University of California - San Francisco, San Francisco, CA, USA, San Francisco, CA  Central Texas Neurology Consultants, Round Rock, TX, USA, Round Rock, TX  Novartis Pharma B.V., Amsterdam, The Netherlands, Haaksbergweg, Netherlands  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharma A.G., Basel, Switzerland, Basel, Switzerland  China Novartis Institutes for BioMedical Research Co., Ltd, Shanghai, China, Shanghai, China, People's Republic of  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, FL, USA, Tampa, FL  University of Muenster, Muenster, Germany, Muenster, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland